PCM
COHR

Prelude Capital Management’s Coherent Inc COHR Stock Holding History

Prelude Capital Management’s Portfolio COHR Stock Details COHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,500
Closed -$397K – 2163
2021
Q2 		$397K Buy
1,500
+500
+50% +$131K 0.01% 1067
2021
Q1 		$253K Buy
+1,000
New +$222K 0.01% 1223
2019
Q4 		– Sell
-10,500
Closed -$1.61M – 2365
2019
Q3 		$1.61M Buy
+10,500
New +$1.52M 0.07% 223
2018
Q2 		– Sell
-400
Closed -$75K – 2042
2018
Q1 		$75K Buy
+400
New +$96.5K 0.01% 945

Other funds holding COHR

WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return
IUHSA
Itau Unibanco Holding S.A. Sao Paulo, Brazil $4.31B AUM 46.57% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
PTC
Private Trust Company Cleveland, Ohio $1.25B AUM 29.12% 1-Year Est. Return

Prelude Capital Management's COHR Position: Q3 2022 in Review

Prelude Capital Management sold out of Coherent Inc (COHR) in Q3 2022, closing a stake of 61,025 shares — an estimated $16.2M sold.

Prelude Capital Management first reported a position in COHR in Q4 2014 and held it in 19 quarters. The position peaked at $16.2M in Q2 2022. 7 funds tracked by Wall St. Rank hold COHR as of Q3 2022.

  • Prelude Capital Management reported no remaining Coherent Inc position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 61,025 Coherent Inc shares in Q3 2022, an estimated $16.2M.
  • Prelude Capital Management first reported a position in Coherent Inc in Q4 2014 and held it in 19 quarters.
  • Prelude Capital Management's Coherent Inc position peaked at $16.2M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Coherent Inc as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.